Targeted EGFR mutation therapies, such as EGFR-TKIs, including erlotinib and gefitinib, have shown to be highly effective in inhibiting glucose consumption in both in vitro and in vivo models of NSCLC (Figure 1) (33, 34). This evidence concerns the gene EGFR and non-small cell lung carcinoma.